NEAL KLEIMAN to Coronary Disease
This is a "connection" page, showing publications NEAL KLEIMAN has written about Coronary Disease.
Connection Strength
1.226
-
Platelet reactivity in patients with subacute stent thrombosis compared with non-stent-related acute myocardial infarction. Am Heart J. 2007 Jan; 153(1):41.e1-6.
Score: 0.214
-
Resistance to antiplatelet therapy. Curr Cardiol Rep. 2005 Jul; 7(4):242-8.
Score: 0.193
-
Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting. Am J Cardiovasc Drugs. 2004; 4(1):31-41.
Score: 0.174
-
Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists. Am Heart J. 2002 Apr; 143(4):594-601.
Score: 0.154
-
Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. Am Heart J. 2009 Apr; 157(4):651-7.
Score: 0.062
-
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J. 2006 Dec; 152(6):1042-50.
Score: 0.053
-
Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. Am Heart J. 2006 Jul; 152(1):157-63.
Score: 0.052
-
Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study. J Thromb Thrombolysis. 2004 Aug; 18(1):31-7.
Score: 0.045
-
Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality. Am J Cardiol. 2004 Jul 15; 94(2):190-2.
Score: 0.045
-
Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. Can J Cardiol. 2004 Jun; 20(8):773-8.
Score: 0.045
-
Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods. Circulation. 2004 Feb 10; 109(5):641-6.
Score: 0.044
-
Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): a new option for the treatment of coronary artery disease. Am J Cardiol. 2003 Nov 07; 92(9B):24N-31N.
Score: 0.043
-
Arterial thrombosis for the interventional cardiologist: from adhesion molecules and coagulation factors to clinical therapeutics. Catheter Cardiovasc Interv. 2003 Oct; 60(2):236-46.
Score: 0.043
-
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation. 2002 May 21; 105(20):2385-91.
Score: 0.039
-
Clinical and economic outcomes of liberal versus selective drug-eluting stent use: insights from temporal analysis of the multicenter Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry. Circulation. 2011 Aug 30; 124(9):1028-37.
Score: 0.018